This technical report provides a set of interim public health considerations to support EU/EEA public health authorities taking decisions on the administration of COVID-19 vaccines to children aged 5 11 years.
A SARS-CoV-2 variant belonging to Pango lineage B.1.1.529, with a high number of S-gene mutations compared to the original virus was detected at the beginning of November 2021. On 26 November 2021 the variant was designated a variant of concern (VOC) and assigned the label Omicron by the World Health Organization (WHO).
This Rapid Risk Assessment assesses the risk posed by the circulation of the Delta variant of SARS-CoV-2 between 1 December 2021 to 31 January 2022, based on modelling scenarios and projected levels of vaccination coverage.
This technical report presents considerations for European Union/European Economic Area (EU/EEA) countries when diagnosing barriers to acceptance and uptake of COVID-19 vaccination, and designing and implementing interventions to increase uptake.
Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0.
The risk assessed in this update is as follows: based on current levels of vaccination coverage and the dominance of the Delta variant in the EU/EEA, what risk does SARS-CoV-2 pose to the general population and the vulnerable population in the coming months?
This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of heterologous schedules) to inform ongoing decision-making in relation to national vaccination policies and strategies in the European Union and European Economic Area (EU/EEA) countries.
This study provides insights for national public health authorities into the factors behind the spread of vaccine misinformation online and the options and capacities needed for responding to it.